PMID- 19204837
OWN - NLM
STAT- MEDLINE
DCOM- 20090421
LR  - 20221212
IS  - 1424-7860 (Print)
IS  - 0036-7672 (Linking)
VI  - 139
IP  - 5-6
DP  - 2009 Feb 7
TI  - The novel anticoagulants: entering a new era.
PG  - 60-4
AB  - During the past five decades, anticoagulant therapy has consisted of rapidly 
      acting parenteral drugs (unfractionated heparin [UFH] low-molecular-weight 
      heparins [LMWH]) for prevention of venous thromboembolism and initial treatment 
      of arterial and venous thromboembolism, whereas vitamin K antagonists (VKA) are 
      used for longer term oral treatment. These drugs act by indirectly inhibiting 
      several activated plasma clotting factors (UFH, LMWH) or by blocking the 
      synthesis of some of them (VKA). In recent years, compounds that specifically 
      block activated coagulation factor X (FXa) or thrombin have been developed. Thus, 
      fondaparinux, and its long-acting derivative idraparinux, are administered 
      subcutaneously. These substances inhibit F Xa indirectly via antithrombin. Small 
      molecules have also been developed that directly block FXa (rivaroxaban, 
      apixaban) or thrombin (dabigatran etexilate) following oral administration. In 
      the present review we discuss the currently available evidence supporting the use 
      of these new anticoagulants, in particular rivaroxaban and dabigatran etexilate, 
      in the setting of thromboprophylaxis following major orthopaedic surgery, and the 
      broader perspectives that these new drugs may open up in the next few years.
FAU - Bounameaux, H
AU  - Bounameaux H
AD  - Division of Angiology and Hemostasis, Department of Internal Medicine, University 
      Hospitals of Geneva and Faculty of Medicine, Geneva, Switzerland. 
      Henri.Bounameaux@medecine.unige.ch
LA  - eng
PT  - Journal Article
PL  - Switzerland
TA  - Swiss Med Wkly
JT  - Swiss medical weekly
JID - 100970884
RN  - 0 (Anticoagulants)
RN  - 0 (Benzimidazoles)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 0 (Morpholines)
RN  - 0 (Pyridines)
RN  - 0 (Thiophenes)
RN  - 12001-79-5 (Vitamin K)
RN  - 9005-49-6 (Heparin)
RN  - 9NDF7JZ4M3 (Rivaroxaban)
RN  - I0VM4M70GC (Dabigatran)
SB  - IM
MH  - Anticoagulants/pharmacology/*therapeutic use
MH  - Arthroplasty, Replacement, Hip
MH  - Arthroplasty, Replacement, Knee
MH  - Benzimidazoles/therapeutic use
MH  - Dabigatran
MH  - Heparin/therapeutic use
MH  - Heparin, Low-Molecular-Weight/therapeutic use
MH  - Humans
MH  - Morpholines/therapeutic use
MH  - *Orthopedic Procedures
MH  - Postoperative Complications/*prevention & control
MH  - Pyridines/therapeutic use
MH  - Rivaroxaban
MH  - Thiophenes/therapeutic use
MH  - Thromboembolism/*prevention & control
MH  - Thrombolytic Therapy/*trends
MH  - Vitamin K/antagonists & inhibitors
EDAT- 2009/02/11 09:00
MHDA- 2009/04/22 09:00
CRDT- 2009/02/11 09:00
PHST- 2009/02/11 09:00 [entrez]
PHST- 2009/02/11 09:00 [pubmed]
PHST- 2009/04/22 09:00 [medline]
AID - smw-12447 [pii]
AID - 10.4414/smw.2009.12447 [doi]
PST - ppublish
SO  - Swiss Med Wkly. 2009 Feb 7;139(5-6):60-4. doi: 10.4414/smw.2009.12447.